We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DNA Minicircle Technique for Stem Cell Reprogramming to Be Commercialized

By LabMedica International staff writers
Posted on 29 Jun 2010
Pluripotent stem cells can be generated from adult human adipose stem cells by using nonintegrating minicircle DNA plasmids that contain the minimum amount of DNA required to reprogram the cells.

The minicircle method has several advantages over conventional virus or bacterial plasmid procedures for cell reprogramming. DNA minicircles do not integrate into the cell's genome and are naturally lost as the cells divide, overcoming some the safety concerns associated with current reprogramming methods. Since minicircles contain no bacterial plasmid backbone DNA, they are able to evade silencing mechanisms that cells naturally use against foreign DNA.

The DNA minicircles are a type of vector that can be either transfected or electroporated into cells to allow for expression of the reprogramming factors. The mini-circle plasmid remains in the cytoplasm of the cell and is eventually lost from the dividing cells. This approach eliminates integration-site expression variability and mutagenesis that is a drawback to viral approaches that have been used to date.

A paper describing the use of DNA minicircles was published in the March 1, 2010, issue of the journal Nature Methods by investigators at Stanford University (Palo Alto, CA, USA). Now it has been announced that the biotechnology company STEMCELLS Technologies Inc. (Vancouver, Canada) has obtained a license from Stanford University to exploit the technology on a commercial basis and intends to market the DNA minicircles as a product called "STEMcircles”.
"The addition of nonviral, nonintegrating STEMcircle reprogramming vectors to our current product offering is an exciting new opportunity for STEMCELL Technologies as a leading provider of standardized, innovative and high quality tools for pluripotent stem cells,” said Alaine Maxwell, product manager of pluripotent stem cell biology at STEMCELL Technologies.

Related Links:
Stanford University
STEMCELLS Technologies Inc.



Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Automated Nucleic Acid Extractor
eLab
New
Urine Drug Test
Instant-view Methadone Urine Drug Test

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries